Accession Number: | 0000899243-21-036767 |
Date: | 2021-09-17 |
Issuer: | BIOMEA FUSION, INC. (BMEA) |
Original Submission Date: |
STERGIOPOULOS SOTIRIOS
C/O BIOMEA FUSION, INC.
726 MAIN STREET
REDWOOD CITY, CA 94063
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-09-17 | P | 34,658 | a | $10.96 | 4,400,000 | indirect |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|
ID | footnote |
---|---|
f1 | the price reported is a weighted average price. the shares were sold in multiple transactions at per share prices ranging from $10.89 to $11.04. the reporting person undertakes to provide upon request to the sec staff, the issuer, or any stockholder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
f2 | these shares are held directly by a2a pharmaceuticals inc. sotirios stergiopoulos is a member of the issuer's board of directors and an affiliate of a2a pharmaceuticals inc. the reporting person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any. |